Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of CBA-1535 in Advanced Solid Tumors
NCT07016997Phase 1Recruiting
- Sponsor
- Chiome Bioscience Inc.
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Trispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CBA-1535 in solid tumor (2 arms), sponsored by Chiome Bioscience Inc. Primary endpoints: Dose limiting toxicity at 21 days and Adverse event at 24 months. Started Jun 2022; status: recruiting.
02
Drugs
CBA-1535
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07016997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016997.